PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. Virchows Archiv
Subscribe to Our Newsletter
You are leaving the U.S. & Canada Research Use Only (RUO) area.
The content you are about to access is intended for other markets and may include products or information not available in the U.S. or Canada.